Literature DB >> 16687066

Central pontine myelinolysis, an update.

Suresh Kumar1, Marjorie Fowler, Eduardo Gonzalez-Toledo, S L Jaffe.   

Abstract

Central pontine myelinolysis (CPM) can be regarded as one of the demyelinating syndromes. First described by Adams et al. in 1959 in their chronic alcoholic patients, it has now been described in the malnourished, the chronically debilitated, the renal, the hepatic and the transplant patient among others. Pathologically, it is defined as a symmetric area of myelin disruption in the center of the basis pontis, although similar symmetric lesions have also been described occurring with CPM as well as independently in other brain areas (extrapontine myelinolysis or EPM) including the cerebellar and neocortical white/gray junctional areas, thalamus and striatum. Possible mechanisms include a hyperosmotically induced demyelination process resulting from rapid intracellular/ extracellular to intravascular water shifts producing relative glial dehydration and myelin degradation and/or oligodendroglial apoptosis. The process most often occurs during rapid rebalancing of the electrolyte parameters in the hyponatremic patient. Avoidance of CPM/EPM is dependent upon recognizing those patients with conditions pre-disposing them to osmotic myelinolysis and then moderating the rate of normalization of the electrolyte imbalance. The morbidity and mortality of CPM/EPM has been greatly reduced by recognition of pre-disposing conditions, increased understanding of the pathophysiology, intensive treatment, and rapid diagnosis and monitoring with advanced neuroimaging.

Entities:  

Mesh:

Year:  2006        PMID: 16687066     DOI: 10.1179/016164106X110346

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  19 in total

1.  Osmotic demyelination syndrome: variable clinical and radiologic response to intravenous immunoglobulin therapy.

Authors:  Santosh B Murthy; Shahram Izadyar; Megha Dhamne; Joseph S Kass; Corey E Goldsmith
Journal:  Neurol Sci       Date:  2012-04-11       Impact factor: 3.307

Review 2.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

3.  Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.

Authors:  Ola Abbas; Ali Shamseddin; Sally Temraz; Ali Haydar
Journal:  BMJ Case Rep       Date:  2013-02-21

4.  Inadvertent hyponatremia leading to acute cerebral edema and early evidence of herniation.

Authors:  Jessica Carpenter; Steve Weinstein; John Myseros; Gilbert Vezina; Michael J Bell
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

5.  [The gynecological TURP syndrome. Severe hyponatremia and pulmonary edema during hysteroscopy].

Authors:  G Serocki; R Hanss; M Bauer; J Scholz; B Bein
Journal:  Anaesthesist       Date:  2009-01       Impact factor: 1.041

Review 6.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26

Review 7.  Structural and microstructral imaging of the brain in alcohol use disorders.

Authors:  Natalie M Zahr
Journal:  Handb Clin Neurol       Date:  2014

Review 8.  Neuroimaging in alcohol use disorder: From mouse to man.

Authors:  Michael Fritz; Anna M Klawonn; Natalie M Zahr
Journal:  J Neurosci Res       Date:  2019-04-22       Impact factor: 4.164

9.  Spectrum of brain abnormalities detected on whole body F-18 FDG PET/CT in patients undergoing evaluation for non-CNS malignancies.

Authors:  Madhavi Tripathi; Abhinav Jaimini; Maria M D'Souza; Rajnish Sharma; Jyotika Jain; Gunjan Garg; Dinesh Singh; Nitin Kumar; Anil K Mishra; Rajesh K Grover; Anupam Mondal
Journal:  Indian J Nucl Med       Date:  2011-04

10.  Central and extrapontine myelinolysis affecting the brain and spinal cord. An unusual presentation of pancreatic encephalopathy.

Authors:  Alejandro Hornik; Federico J Rodriguez Porcel; Caroline Agha; Murray Flaster; Sarkis Morales Vidal; Michael J Schneck; John Lee; José Biller
Journal:  Front Neurol       Date:  2012-10-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.